ReviewFrontiers in microbiology2019
Development of Small-Molecule Inhibitors Against Zika Virus Infection.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Discovery and computational characterization of ZIKV envelope-targeted peptides from a subtractive phage display library.PloS one · 2026Article
- Identification and Evaluation of Natural Compounds as Potential Inhibitors of NS2B-NS3 Zika Virus Protease: A Computational Approach.Molecular biotechnology · 2025Article
- Review
- Advances in antiviral strategies targeting mosquito-borne viruses: cellular, viral, and immune-related approaches.Virology journal · 2025Review
- Cyclin Dependent Kinases in Antiviral Drug Discovery.Current medicinal chemistry · 2025Review
- ZIKV Inhibitors Based on Pyrazolo[3,4-ACS omega · 2023Article
- Therapeutic Potential of Antiviral Peptides against the NS2B/NS3 Protease of Zika Virus.ACS omega · 2023Article
- Evaluating Known Zika Virus NS2B-NS3 Protease Inhibitor Scaffolds via In Silico Screening and Biochemical Assays.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections.Molecular biotechnology · 2023Review
- Broad-Spectrum Small-Molecule Inhibitors Targeting the SAM-Binding Site of Flavivirus NS5 Methyltransferase.ACS infectious diseases · 2023Article
- The Dimeric Peptide (KKYRYHLKPF)Viruses · 2023Article
- Antiviral effects of the fused tricyclic derivatives of indoline and imidazolidinone on ZIKV infection and RdRp activities of ZIKV and DENV.Virus research · 2023Article
- Lessons Learned and Yet-to-Be Learned on the Importance of RNA Structure in SARS-CoV-2 Replication.Microbiology and molecular biology reviews : MMBR · 2022Review
- Zika Virus Inhibitors Based on a 1,3-Disubstituted 1Molecules (Basel, Switzerland) · 2022Article
- A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model.PloS one · 2022Article
- Brevinin-2GHk, a Peptide Derived from the Skin ofViruses · 2021Article
- 4,7-Disubstituted 7Molecules (Basel, Switzerland) · 2021Article
- Palmitoleate Protects against Zika Virus-Induced Placental Trophoblast Apoptosis.Biomedicines · 2021Article
- Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals.Frontiers in pharmacology · 2021Review
- Scorpion-Derived Antiviral Peptides with a Special Focus on Medically Important Viruses: An Update.BioMed research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the outbreak of infectious disease caused by Zika virus (ZIKV) has posed a major threat to global public health, calling for the development of therapeutics to treat ZIKV disease. Here, we have described the different stages of the ZIKV life cycle and summarized the latest progress in the development of small-molecule inhibitors against ZIKV infection. We have also discussed some general strategies for the discovery of small-molecule ZIKV inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.